2 citations
,
January 2025 in “Cutis” This review examined the dermatologic side effects and potential treatments benefits of metformin and GLP-1/GIP agonists in managing skin conditions related to hormonal and immune effects in individuals with type 2 diabetes who are overweight or obese.
4 citations
,
February 2025 in “Pharmaceuticals” In this study, voglibose, commonly used for diabetes management, was found to reduce melanin synthesis and inhibit melanogenic signaling pathways in B16F10 melanoma cells, suggesting it could be repurposed for treating hyperpigmentation disorders with confirmed topical safety in human tests.
10 citations
,
August 2012 in “Clinical Pharmacokinectics” This study found that type 2 diabetes mellitus does not affect the pharmacokinetics of metformin in obese pregnant women with PCOS, suggesting no need for dosage adjustments.
December 2014 in “Endocrinología y nutrición” The woman's rare combination of diseases suggests an unknown factor may predispose individuals to multiple endocrine diseases.
July 2026 in “Journal of the American Academy of Dermatology” GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.